Vanessa Ghislain

Learn More
BACKGROUND The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies. METHODS We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu(More)
  • 1